Tuesday, 15th December Eradicate Cancer 2020

• Normal and Neoplastic Stem Cells - Irv Weissman

Introduction: Jacques Miller’s continuing legacy
Peter Doherty Nobel Laureate (Doherty Institute, Melbourne)

• Putting the BiTE on CAR-T cells: Engaging T cells as Cancer killers - Simon Harrison

• CARs and Armoured CARs: Improving CAR T cell therapy for cancer - Renier Brentjens
• T cell Immunotherapy via Native and Chimeric Receptors - Helen Heslop
• TRuC™-T cells: Redefining T cell therapy for cancer - Robert Hofmeister
• Factors impacting outcomes of CD19 CAR-T cells for B cell malignancies - Cameron Turtle
• Factors Associated with Outcomes of Repeat CD19-targeted CAR T cell infusions for Refractory B cell Malignancies - Jordan Gauthier
• CAR-T cells targeting fibroblast activation protein (FAP) for the treatment of glioblastoma - Lisa Ebert

• Harnessing the cellular immunity to fight virus-associated cancers - Rajiv Khanna
• A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies - Jonathan Cebon
• The immune landscape as a determinant of outcome in allogeneic stem cell transplantation as anti-cancer therapy - David Ritchie
• Phase I Clinical Trial evaluating Polynucleotide Immunotherapy for HPV associated Oropharyngeal Cancer - J Chandra
• Predicting immunotherapy outcomes in melanoma patients - Jessica Da Gama Duarte
• Skinning a cat - the dilemma of choice for treating B cell malignancies with immunotherapy  - Miles Prince
• Targeting PTPN2 to enhance CAR T cell mediated anti-tumour immunity  - Florian Wiede

Harnessing Myeloid Cells for cancer immunotherapy: The ATAKTM Myeloid Cell Platform
Daniel Getts (Myeloid Therapeutics PL)

• Harnessing Myeloid Cells for cancer immunotherapy: The ATAK^TM Myeloid Cell Platform - Daniel Getts

• Enhancing CAR T cell therapy by genetic modification with Flt3L - Phil Darcy
• Dual specificity CAR-T cells targeting TAG-72 and CD47 for the treatment of ovarian cancer  - Vera Evtimov
• New Strategy for Making CAR-T Cells with an Early Memory Phenotype and Improved Anti-tumour Efficacy - Joe Jiang Zhu
• Enhancing CAR T cell therapy by enabling their interaction with antigen-presenting cells - Clare Slaney
• Development of GD2-specific CAR T cells optimized for the treatment of brain cancer - Tessa Gargett
• Novel EGFRvIII specific CART cells are an effective treatment for glioblastoma  - Misty Jenkins
• In vitro and in vivo evaluation of the LGR5 receptor as a CAR-T target for solid tumour immunotherapy - Veronika Bandara

• Integrin-linked kinase regulates growth and senescence in colorectal cancer cell lines - Saleh Almasabi
• EXPRESSION OF IMMUNOINHIBITORY MOLECULES PD-L1 AND PD-L2 BY DENDRITIC CELLS - Annabelle B Blum
• Mechanism of enhancing the response to checkpoint inhibitors without increasing toxicity. - Angus Dalgleish
• Repurposing Venetoclax and Ruxolitinib to improve stem cell transplant outcomes - Joanne E Davis
• Targeting Cutaneous T Cell Lymphoma with novel CAR-T cells - Vera Evtimov
• Spliced peptides: a novel class of targets for cancer immunotherapy - Pouya Faridi
• Are nanomedicines being underutilised in the clinic for treatment of triple-negative breast cancer? - Ruqaya Maliki
• Development of Novel Autophagy Inhibitors Based Anti-Cancer Combination Therapy - Yomna Saleh
• Success and failure of adoptive T cell therapy against cancer - Christina Scheffler
• SEB can support CAR T cells against solid tumours - Bianca von Scheidt
• CRISPR/Cas9 gene knockout in CAR-T cells enhancing persistence and anti-tumor activity in vivo - Runzhe Shu
• Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors - Anna Vilgelm